Follow The Filings

NDAQ iShares Nasdaq Biotech Indx

Financials, filed as ISHARES NASDAQ BIOTECH INDX (ETF), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.5%
  • $8.1M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed iShares Nasdaq Biotech Indx.

Who owns this now

Largest portfolio weights among holders, up to 1.5% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 1.5%

Who owns NDAQ

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 1.5%, was 2.4% Reduce −31.4% 42,595 $8.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NDAQ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NDAQ insider trades
  • $21.7M bought by 2 insiders
  • $7.9M sold by 4 insiders outside a trading plan
  • $79.1M sold by 4 insiders under 10b5-1 plans
  1. Jeremy Skule EVP, Cso
    Planned sale
    $107K 1,125 shares at $95.00 1.2% of stake
    Traded Oct 20 Filed Oct 22
    ↗
  2. Jeremy Skule EVP, Cso
    Planned sale
    $106K 1,125 shares at $94.13 1.1% of stake
    Traded Oct 12 Filed Oct 14
    ↗
  3. Jeremy Skule EVP, Cso
    Planned sale
    $107K 1,125 shares at $95.00 1.1% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  4. Jeremy Skule EVP, Cso
    Planned sale
    $106K 1,125 shares at $94.22 1.1% of stake
    Traded Sep 10 Filed Sep 14
    ↗
  5. Jeremy Skule EVP, Cso
    Planned sale
    $213K 2,250 shares at $94.75 2.2% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  6. Pc Nelson Griggs Pres. Capital Access Platforms
    Sale
    $310K 3,226 shares at $96.16 1.6% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  7. Bradley J Peterson EVP, CIO
    Sale
    $573K 6,000 shares at $95.55 4.7% of stake
    Traded Aug 7 Filed Aug 11
    ↗
  8. Bryan Everard Smith EVP, CPO
    Planned sale
    $148K 1,556 shares at $95.07 2.2% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  9. Pc Nelson Griggs Pres. Capital Access Platforms
    Sale
    $1.1M 11,010 shares at $96.35 5.1% of stake
    Traded Jul 29 Filed Jul 31
    ↗
  10. Bradley J Peterson EVP, CIO
    Sale
    $1.2M 13,000 shares at $92.61 9.2% of stake
    Traded Jul 24 Filed Jul 28
    ↗
  11. Pc Nelson Griggs Pres. Capital Access Platforms
    Sale
    $1.7M 17,787 shares at $93.42 7.6% of stake
    Traded Jul 24–27 Filed Jul 28
    ↗
  12. Bryan Everard Smith EVP, CPO
    Planned sale
    $240K 3,000 shares at $80.00 4.2% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  13. Ab Investor 10% owner, +1 joint filer
    Buy
    $4.9M 56,782 shares at $85.98 +0.1% to stake
    Traded Jun 11 Filed Jun 15
    ↗
  14. Bryan Everard Smith EVP, CPO
    Planned sale
    $261K 3,000 shares at $86.91 4% of stake
    Traded Jun 11 Filed Jun 15
    ↗
  15. Pc Nelson Griggs Pres. Capital Access Platforms
    Sale
    $472K 5,093 shares at $92.62 2.1% of stake
    Traded May 18 Filed May 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 36 stock grants, 29 share withholdings for taxes, 4 gifts, and 4 option exercises.

Congress

4 members of Congress traded NDAQ in the last three years: 11 buys and 4 sales. 5 members listed it in 2025 annual reports.

All Congress trades
  1. April McClain Delaney D-MD-6Child Sell $100K–$250K Aug 25 filed Sep 9
  2. Alan Armstrong R-OK Sell $50K–$100K Mar 27 filed Jul 21
  3. April McClain Delaney D-MD-6Child Buy $1K–$15K Apr 24 filed May 6
  4. April McClain Delaney D-MD-6Child Buy $1K–$15K Mar 31 filed Apr 6
  5. April McClain Delaney D-MD-6Child Buy $1K–$15K Mar 18 filed Apr 6
  6. April McClain Delaney D-MD-6Child Buy $1K–$15K Mar 10 filed Apr 6

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,1.02,2.03,9.01 Filing Doc
8-K 5.07 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated about 19 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.06B $7.4B $8.26B
Gross profit $3.9B $4.65B $5.25B
Gross margin * 64.2% 62.8% 63.5%
Net income $1.06B $1.12B $1.79B
Net margin * 17.5% 15.1% 21.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $9.1B $7.79B $8B
Total non-current assets * $23.2B $22.61B $23.05B
Total assets $32.29B $30.4B $31.05B
Total current liabilities $9.02B $7.9B $7.96B
Total non-current liabilities * $12.44B $11.29B $10.86B
Total equity $10.82B $11.19B $12.23B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.7B $1.94B $2.26B
Cash from investing -$5.99B -$0.953B -$1.1B
Cash from financing $4.22B -$2.56B -$2.95B
Net change in cash $0.124B -$2.11B -$1.07B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.